BBBalram Bhargava

Balram Bhargava

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Balram Bhargava has a total of 256 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retraction
    Open Access

    Retraction Note: Adipose tissue derived mesenchymal stem cells are better respondents to TGFβ1 for in vitro generation of cardiomyocyte‑like cells

    by Anupama Kakkar, Sushmita Bose Nandy, Suchi Gupta, Balram Bharagava, Balram Airan, Sujata Mohanty

  • Open Access

    Population-based surveillance for hypertension awareness, treatment, and control in nine districts - India Hypertension Control Initiative, 2018–19

    by Prabhdeep Kaur, Kamaraj Pattabi, Amirthammal Gunasekaran, Vettrichelvan Venkatasamy, Azhagendran Sivalingam, Sabarinathan Ramasamy, Sailaja Bitragunta, Tapas Chakma, Sampada D. Bangar, Meenakshi Sharma, et al.

    Hypertension control is the crucial indicator for cardiovascular disease programs. We conducted a baseline cross-sectional survey to estimate hypertension awareness, treatment, and control in the selected districts in 2018–19, where the India Hypertension Control Initiative is being implemented. We conducted cross-sectional surveys in nine project districts for 18–69 years age group. The sample size was 624 per district. The study population was individuals with raised BP/diagnosed HT. We estimated the proportion and 95% confidence intervals (CI) for each district’s awareness, treatment, and control. We computed unadjusted and adjusted prevalence ratios (APR) with 95% CI for factors associated with BP control. Hypertension was defined as systolic blood pressure (SBP) > = 140 or diastolic blood pressure (DBP) > = 90 mmHg or treatment in the previous two weeks. Control was defined as SBP < 140 and DBP < 90 mmHg. Among 7047 who had hypertension, 52.4% were aware, 40.8% were on treatment, and 14.5% had BP control. BP control was below 5% in two districts, 5–15% in three districts, and more than 15% in four districts. Among hypertensives aware of the diagnosis, the factors (APR with 95% CI) associated with control were lack of alcohol consumption [1.28 (1.09–1.52)], recent visit to government [1.98 (1.57–2.50)] or private facility [1.99 (1.61–2.46)] and treatment with single drug [2.40 (1.98–2.90)] or multiple drugs [2.84 (2.27–3.55)]. The simple, rapid population-based surveys can document awareness, treatment, and control changes. Improving access to treatment for hypertension through the public or private sector should be a high priority for India.


  • Open Access

    India Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022

    by Prabhdeep Kaur, Manikandanesan Sakthivel, Vettrichelvan Venkatasamy, Padmaja Jogewar, Sandeep S. Gill, Abhishek Kunwar, Meenakshi Sharma, Anupam Khungar Pathni, Kiran Durgad, Swagata Kumar Sahoo, et al.

    Background: Hypertension treatment coverage is low in India. A stepwise simple treatment protocol is one of the strategies to improve hypertension treatment in primary care. We estimated the effectiveness of various protocol steps to achieve blood pressure (BP) control in public sector health facilities in Punjab and Maharashtra, India, where the India Hypertension Control Initiative (IHCI) was implemented. Methods: We analyzed the records of people enrolled for hypertension treatment and follow-up under IHCI between January 2018 and December 2021 in public sector primary and secondary care facilities across 23 districts from two states. Each state followed a different treatment protocol. We calculated the proportion with controlled BP at each step of the protocol. We also estimated the mean decline in BP pre- and post-treatment. Results: Of 281,209 patients initiated on amlodipine 5 mg, 159,292 continued on protocol drugs and came for a follow-up visit during the first quarter of 2022. Of 33,450 individuals who came for the follow-up in Punjab and 125,842 in Maharashtra, 70% and 76% had controlled BP, respectively, at the first step with amlodipine 5 mg. In Punjab, at the second step with amlodipine 10 mg, the cumulative BP control increased to 75%. A similar 5% (76%–81%) increase was seen in the second step after adding telmisartan 40 mg in Maharashtra. Overall, the mean (SD) systolic blood pressure (SBP) decreased by 16 mmHg from 148 (15) mmHg at the baseline in Punjab. In Maharashtra, the decline in the mean (SD) SBP was about 15 mmHg from the 144 (18) mmHg baseline. Conclusion: Simple drug- and dose-specific protocols helped achieve a high control rate among patients retained in care under program conditions. We recommend treatment protocols starting with a single low-cost drug and escalating with the same or another antihypertensive drug depending on the cost and availability.


  • Open Access

    The India Hypertension Control Initiative–early outcomes in 26 districts across five states of India, 2018–2020

    by Prabhdeep Kaur, Abhishek Kunwar, Meenakshi Sharma, Kiran Durgad, Sudhir Gupta, Balram Bhargava

    Hypertension is the leading single preventable risk factor for cardiovascular disease. The India Hypertension Control Initiative (IHCI) project was designed to improve hypertension control in public sector clinics. The project was launched in 2018–2019 in 26 districts across five states: Punjab (5), Madhya Pradesh (3), Kerala (4), Maharashtra (4), and Telangana (10), with five core strategies: standard treatment protocol, reliable supply of free antihypertensive drugs, team-based care, patient-centered care, and an information system to track individual patient treatment and blood pressure control. All states implemented simple treatment protocols with three drugs: a long-acting dihydropyridine calcium channel blocker (amlodipine), angiotensin receptor blocker (telmisartan), and thiazide or a thiazide-like diuretic (hydrochlorothiazide or chlorthalidone). Medication supplies were adequate to support at least one month of treatment. Overall, 570,365 hypertensives were enrolled in 2018–2019; 11% did not have follow-up visits in the most recent 12 months. Clinic-level blood pressure control averaged 43% (range 22–79%) by Jan-March, 2020. The proportion of the estimated people with hypertension who had it controlled and documented in public clinics increased three-fold, albeit from very low levels (1.4–5.0%). The IHCI demonstrated the feasibility of implementing protocol-based hypertension treatment and control supported by a reliable drug supply and accurate information systems at scale in Indian primary health care facilities. Lessons from the IHCI’s initial phase will inform plans to improve screening in health care facilities, increase retention in care, and ensure a sustained supply of drugs as part of a nationwide hypertension control program.


  • Open Access

    ‘Imperfect but useful’: pandemic response in the Global South can benefit from greater use of mathematical modelling

    by Sandip Mandal, Kanchan Parchani, Nimalan Arinaminpathy, Swarup Sarkar, Balram Bhargava, Samiran Panda

    Mathematical modelling has been a helpful resource for planning public health responses to COVID-19. However, there is a need to improve the accessibility of models built within country contexts in the Global South. Immediately following the overwhelming ‘second wave’ of COVID-19 in India, we developed a user-friendly, web-based modelling simulator in partnership with the public health experts and health administrators for subnational planning. The purpose was to help policy-makers and programme officials at the state and district levels, to construct model-based scenarios for a possible third wave. Here, we describe our experiences of developing and deploying the simulator and propose the following recommendations for future such initiatives: early preparation will be the key for pandemic management planning, including establishment of networks with potential simulator users. Ideally, this preparedness should be conducted during ‘peace time’, and coordinated by agencies such as WHO. Second, flexible modelling frameworks will be needed, to respond rapidly to future emergencies as the precise nature of any pandemic is impossible to predict. Modelling resources will, therefore, need to be rapidly adaptable to respond as soon as a novel pathogen emerges. Third, limitations of modelling must be communicated clearly and consistently to end users. Finally, systematic mechanisms are required for monitoring the use of models in decision making, which will help in providing modelling support to those local authorities who may benefit most from it. Overall, these lessons from India can be relevant for other countries in the South-Asian-Region, to incorporate modelling resources into their pandemic preparedness planning.


  • Open Access

    Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine

    by Gajanan Sapkal, Rajni Kant, Gaurav Dwivedi, Rima R Sahay, Pragya D Yadav, Gururaj R Deshpande, Rajeev Singh, Dimpal A Nyayanit, Deepak Y Patil, Anita M Shete-Aich, et al.

    Within a short span of time severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines developed through usage of different platforms have been approved across the globe. Such vaccines have acted as disease modifying tools by reducing the severity of the clinical course of infection and mortality due to coronavirus disease 2019 (COVID-19). However, the recent emergence of SARS-CoV-2 variant of concern (VOC) Omicron with its high transmissibility, has led to rapid surge in the number of COVID-19 cases including the breakthroughs and re-infections. 1 Against this background, marked immune escape potential of the Omicron variant has been at the centre stage of discussion. There has also been growing interest in mix and match booster vaccination against COVID-19 across the globe in the light of newly emerging VOCs and many countries have started following the heterologous booster vaccination approach. 2 Preliminary studies have reported the safety, and improved humoral and cellular immune responses with a heterologous boost approach than a homologous one. 2


  • Open Access

    Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

    by Rajni Kant, Gaurav Dwivedi, Kamran Zaman, Rima R Sahay, Gajanan Sapkal, Himanshu Kaushal, Dimpal A Nyayanit, Pragya D Yadav, Gururaj Deshpande, Rajeev Singh, et al.

    COVID-19 vaccination program was rolled out in India on January 16th 2021. 1 The whole virion inactivated BBV152 (Covaxin) and AstraZeneca’s ChAdOx1-nCov-19 (Covishield) were the two vaccines initially included under this program. 2, 3, 4, 5 Frontline workers including healthcare professionals, elderly above the age of 60 and adults with co-morbidity were prioritized for vaccination before reaching out to all the adults. During expansion of the aforementioned vaccination program, a group of participants in the northern state of Uttar Pradesh received Covishield (CS) as the first dose followed by inadvertent administration of Covaxin (CV) as the second dose. We studied the safety and immunogenicity of this heterologous prime-boost COVID-19 vaccination. A total of 98 vaccine recipients who had completed two weeks or more after the second dose of vaccine were included in this study. Three groups of participants were recruited during May to June 2021: heterologous group (n = 18, first dose CS, second dose CV administered at an interval of six weeks), among them, 11 were male (M/F:11/7) with a median age of 62 year (IQR 54.25–69.75). A comorbid condition (hypertension) was reported in one participant. Homologous CS group (n = 40, 22 were males and the rest were female (M/F:22/18) with a median age of 65.5 years (IQR 62–69) and co-morbidity was observed among 4 participants who received two CS-vaccine doses at six weeks interval. The homologous CV-group (n = 40, two vaccine doses administered at four weeks interval including 23 females (M/F:17/23) with a median age of 56 year (IQR 45.5–63) and 3 with co-morbidities ( Supplementary Table 1 ) ( Supplementary Figure S1 ).


  • Open Access

    Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

    by Pragya D Yadav, Rima R Sahay, Gajanan Sapkal, Dimpal Nyayanit, Anita M Shete, Gururaj Deshpande, Deepak Y Patil, Nivedita Gupta, Sanjay Kumar, Priya Abraham, et al.

    The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern, was associated with the second wave of pandemic in India during March–May 2021. Delta variant has outpaced the other two sub-lineages Kappa (B.1.617.1) and B.1.617.3 and was responsible for 90% of the cases reported in India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4


  • Open Access

    Responsible travel to and within India during the COVID-19 pandemic

    by Sandip Mandal, Nimalan Arinaminpathy, Balram Bhargava, Samiran Panda

    Following the ‘second wave’ of COVID-19 in India, there has been an upsurge of domestic travel to holiday destinations, particularly Himalayan mountain towns. Modelling suggests that such travel could enhance the peak of a third wave in these states by almost 50%. Principles of ‘responsible travel’ should be adhered to.